Erdheim–Chester disease. Literature review and clinical case

Erdheim–Chester disease (ECD) is a rare and frequently neglected disease, usually with a poor prognosis. The first two cases of ECD were reported by Austrian pathologist: Jakob Erdheim and his apprentice student William Chester in 1930. The etiology and disease incidence are unknown. One of the main components of this disorder is a chronic uncontrollable inflammation. Clinical manifestations of the disease can be very different. ECD affects predominantly adults, usually male population. There is no effective treatment developed yet. In 2016 ECD was classified as histiocytic neoplasm by the World Health Organization and was categorized as “tumors of histiocytes and dendritic cells”. More than half of patients testing positive for the BRAF mutation. There is a Erdheim–Chester Disease Global Alliance (ECDGA), which try to unite and provide with information about diagnostics and treatment of this rare disease both patients and doctors. Today, there are 571 registered patients and only one from Russia. The final diagnosis is made on the basis of histological finding such as infiltration with foamy histiocytes, signs of inflammation and Touton giant cells. Immunohistological analysis is usually CD68 and XIIIa positive. There are radiological finding indicating a possible association with the disease. There is this specific, almost pathognomonic scintigraphic picture of the skeleton, “coated” aorta, “hairy kidney” patterns on computer tomography. We demonstrate a clinical case of a patient with a newly diagnosed ECD with bone and connective tissue involvement, with manifestation of this disease more than 10 years ago. It took four months to make the final diagnosis. There were three biopsies and a wide range of other diagnostic procedures.

1. Estrada-Veras J.I., O’Brien K.J., Boyd L.C. et al. The clinical spectrum of Erdheim–Chester disease: an observational cohort study. Blood Adv 2017;1(6):357–66. DOI: 10.1182/bloodadvances.2016001784.

2. Emile J.F., Abla O., Fraitag S. et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127(22):2672–81. DOI: 10.1182/blood-2016-01-690636.

3. Arnaud L., Gorochov G., Charlotte F. et al. Systemic perturbation of cytokine and chemokine networks in Erdheim–Chester disease: a single-center series of 37 patients. Blood 2011;117(10):2783–90. DOI: 10.1182/blood-2010-10-313510.

4. Tran T.A., Fabre M., Pariente D. et al. Erdheim–Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol 2009;31(10):782–6. DOI: 10.1097/MPH.0b013e3181b76827.

5. Vallonthaiel A.G., Mridha A.R., Gamanagatti S. et al. Unusual presentation of Erdheim–Chester disease in a child with acute lymphoblastic leukemia. World J Radiol 2016;8(8):757–63. DOI: 10.4329/wjr.v8.i8.757.

6. Campo E., Harris N.L., Jaffe E.S. et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer 2017. P. 586.

7. Emile J.F., Charlotte F., Amoura Z., Haroche J. BRAF mutations in Erdheim– Chester disease. J Clin Oncol 2013;31(3):398. DOI: 10.1200/JCO.2012.46.9676.

8. Cangi M.G., Biavasco R., Cavalli G. et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim–Chester disease. Ann Rheum Dis 2015;74(8):1596–602. DOI: 10.1136/annrheumdis-2013-204924.

9. Emile J.F., Diamond E.L., Hélias-Rodzewicz Z. et al. Recurrent RAS and PIK3CA mutations in Erdheim–Chester disease. Blood 2014;124(19):3016–9. DOI: 10.1182/blood-2014-04-570937.

10. Diamond E.L., Abdel-Wahab O., Pentsova E. et al. Detection of an NRAS mutation in Erdheim–Chester disease. Blood 2013;122(6):1089–91. DOI: 10.1182/blood-2013-02-482984.

11. Chester W. Uber lipoid granulomatose. Virchows Arch (Pathol Anat Phys) 1930;279:561–602.

12. http://erdheim-chester.org.

13. Haroche J., Arnaud L., Amoura Z. Erdheim–Chester disease. Curr Opin Rheumatol 2012;24(1):53–9. DOI: 10.1097/BOR.0b013e32834d861d.

14. http://www.histio.org.

15. Dion E., Graef C., Miquel A. et al. Bone involvement in Erdheim–Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 2006;238(2):632–9.

16. Scolaro J.C., Peiris A.N. The Hairy Kidney of Erdheim–Chester Disease. Mayo Clin Proc 2018;93(5):671. DOI: 10.1016/j.mayocp.2018.03.003.

17. Kraniotis P., Daoussis D. Periaortitis, hairy kidneys and bone lesions. Rheumatology (Oxford) 2016;55(12):2118. DOI: 10.1093/rheumatology/kew331.

18. Lee H.J., Lee K.Y., Shin D.Y. et al. A case of Erdheim–Chester disease with asymptomatic renal involvement. Cancer Res Treat 2012;44(2):146–50. DOI: 10.4143/crt.2012.44.2.146.

19. Serratrice J., Granel B., De Roux C. et al. “Coated aorta”: a new sign of Erdheim– Chester disease. J Rheumatol 2000;27(6):1550–3.

20. Dave A.A., Gutschow S.E., Walker C.M. A case of incidentally-diagnosed Erdheim–Chester disease. Cureus 2016;8(9):e781. DOI: 10.7759/cureus.781.

21. Suzuki H., Wanibuchi M., Komatsu K. et al. Erdheim–Chester disease involving the central nervous system with the unique appearance of a coated vertebral artery. NMC Case Rep J 2016;3(4):125–8. DOI: 10.2176/nmccrj.cr.2015-0331.

22. Diamond E.L., Hatzoglou V., Patel S. et al. Diffuse reduction of cerebral grey matter volumes in Erdheim–Chester disease. Orphanet J Rare Dis 2016;11(1): 109. DOI: 10.1186/s13023-016-0490-3.

23. Lachenal F., Cotton F., Desmurs-Clavel H. et al. Neurological manifestations and neuroradiological presentation of Erdheim–Chester disease: report of 6 cases and systematic review of the literature. J Neurol 2006;253(10):1267–77. DOI: 10.1007/s00415-006-0160-9.

24. Nicolazzi M.A., Carnicelli A., Fuorlo M. et al. Cardiovascular involvement in Erdheim–Chester disease: a case report and review of the literature. Medicine (Baltimore) 2015t;94(43):e1365. DOI: 10.1097/MD.0000000000001365.

25. Lee K., Kim H.R., Roh J. et al. Erdheim– Chester disease presenting as an anterior mediastinal tumor without skeletal involvement. Korean J Thorac Cardiovasc Surg 2018;51(3):223–6. DOI: 10.5090/kjtcs.2018.51.3.223.

26. Razanamahery J., Jacquier F., Humbert S. A rare case of chylous ascites. Gastroenterology 2017;153(4):903–5. DOI: 10.1053/j.gastro.2017.04.008.

27. Balasubramanian G., Modiri A., Affi M. et al.A fatal case of Erdheim–Chester disease with hepatic involvement. ACG Case Rep J 2017;4:e95. DOI: 10.14309/crj.2017.95.

28. Ambrosini V., Savelli F., Merli E. et al. F-18 FDG PET/CT detects muscle involvement in Erdheim–Chester disease. Clin Nucl Med 2012;37(2):196–7. DOI: 10.1097/RLU.0b013e31823e9d54.

29. Martineau P., Pelletier-Galarneau M., Zeng W. The imaging findings of Erdheim–Chester disease: a multimodality approach to diagnosis and staging. World J Nucl Med 2017;16(1):71–4. DOI: 10.4103/1450-1147.181149.

30. Sabino D., do Vale R.H.B., Duarte P.S. et al. Complementary findings on 18F-FDG PET/CT and 18F-NaF PET/CT in a patient with Erdheim–Chester disease. Radiol Bras 2017;50(3):202–3. DOI: 10.1590/0100-3984.2015.0172.

31. Nikpanah M., Kim L., Mirmomen S.M. et al. Abdominal involvement in Erdheim– Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation. Eur Radiol 2018;28(9):3751–9. DOI: 10.1007/s00330-018-5326-1.

32. Mirmomen S.M., Sirajuddin A., Nikpanah M. et al. Thoracic involvement in Erdheim–Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation. Eur Radiol 2018;28(11):4635–42. DOI: 10.1007/s00330-018-5421-3.

33. Boissel N., Wechsler B., Leblond V. Treatment of refractory Erdheim–Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001;135(9):844–5.

34. Gaspar N., Boudou P., Haroche J. et al. Highdose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica 2006;91(8):1121–5.

35. Braiteh F., Boxrud C., Esmaeli B., Kurzrock R. Successful treatment of Erdheim–Chester disease, a non-Langerhans-cell histiocytosis, with interferonalpha. Blood 2005;106(9):2992–4. DOI: 10.1182/blood-2005-06-2238.

36. Haroche J., Amoura Z., Trad S.G. et al. Variability in the efficacy of interferon-alpha in Erdheim–Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006;54(10):3330–6. DOI: 10.1002/art.22165.

37. Arnaud L., Hervier B., Néel A. et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim–Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117(10):2778–82. DOI: 10.1182/blood-2010-06-294108.

38. Aouba A., Georgin-Lavialle S., Pagnoux C. et al. Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. Blood 2010;116(20):4070–6. DOI: 10.1182/blood-2010-04-279240.

39. Aubert O., Aouba A., Deshayes S. et al. Favorable radiological outcome of skeletal Erdheim–Chester disease involvement with anakinra. Joint Bone Spine 2013;80(2):206–7. DOI: 10.1016/j.jbspin.2012.07.005.

40. Goyal G., Shah M.V., Call T.G. et al. Efficacy of biological agents in the treatment of Erdheim–Chester disease. Br J Haematol 2018;183(3):520–4. DOI: 10.1111/bjh.14997.

41. Tomelleri A., Cavalli G., De Luca G. et al. Treating heart inflammation with interleukin-1 blockade in a case of Erdheim–Chester disease. Front Immunol 2018;9:1233. DOI: 10.3389/fimmu.2018.01233

42. Diamond E.L., Abdel-Wahab O., Durham B.H. et al.Anakinra as efficacious therapy for 2 cases of intracranial Erdheim–Chester disease. Blood 2016;128(14):1896–8. DOI: 10.1182/blood-2016-06-725143.

43. Nikonova A., Esfahani K., Chausse G. et al. Erdheim–Chester disease: the importance of information integration. Case Rep Oncol 2017;10(2):613–9. DOI: 10.1159/000477658.

44. Hyman D.M., Puzanov I., Subbiah V. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373(8):726–36. DOI: 10.1056/NEJMoa1502309.

45. Mirouse A., Savey L., Domont F. et al. Systemic vasculitis associated with vemurafenib treatment: case report and literature review. Medicine (Baltimore) 2016;95(46):e4988. DOI: 10.1097/MD.0000000000004988.

46. Bhatia A., Ulaner G., Rampal R. et al. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica 2018;103(4):e177–80. DOI: 10.3324/haematol.2017.185298.

47. Cohen Aubart F., Emile J.F., Carrat F. et al. Targeted therapies in 54 patients with Erdheim–Chester disease, including follow-up after interruption (the LOVE study). Blood 2017;130(11):1377–80. DOI: 10.1182/blood-2017-03-771873.

48. Haroche J., Amoura Z., Charlotte F. et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim–Chester histiocytosis. Blood 2008;111(11):5413–5. DOI: 10.1182/blood-2008-03-148304.

49. Janku F., Amin H.M., Yang D. et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010;28(31):e633–6. DOI: 10.1200/JCO.2010.29.9073.

50. Dagna L., Corti A., Langheim S. et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim–Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012;30(28):e286–90. DOI: 10.1200/JCO.2012.41.9911.

51. Cives M., Simone V., Rizzo F.M. et al. Erdheim–Chester disease: a systematic review. Crit Rev Oncol Hematol 2015;95(1):1–11. DOI: 10.1016/j.critrevonc.2015.02.004.

52. Goyal G., Shah M.V., Call T.G. et al. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim–Chester disease. Blood Cancer J 2017;7(12):647. DOI: 10.1038/s41408-017-0034-7.

53. Azadeh N., Tazelaar H.D., Gotway M.B. et al. Erdheim–Chester disease treated successfully with cladribine. Respir Med Case Rep 2016;18:37–40. DOI: 10.1016/j.rmcr.2016.03.008.

54. Byalik T.E., Yakimovich O.Yu., Makhonova L.A. et al. Disseminated juvenile xanthogranuloma in adults. Case report. Klinicheskaya onkogematologiya = Clinical Oncohematology 2011;4(4):329–33. (In Russ.).

55. Poiroux L., Paycha F., Polivka M., Ea H.K. Efficacy of zoledronic acid in Erdheim–Chester disease: a case report. Joint Bone Spine 2016;83(5):573–5. DOI: 10.1016/j.jbspin.2015.10.010

56. Vasilyev V.I., Sokol E.V., Kokosadze N.V. et al. The differential diagnosis of Erdheim–Chester disease and IgG4-related diseases. Yerapevticheskiy arkhiv = Therapeutic Archive 2016;88(5):70–6. (In Russ.).

57. Krylov A.S., Ryzhkov A.D., Odzharova A.A. et al. The role of nuclear medicine in the diagnosis of Erdheim– Chester disease. A series of clinical observations. Onkogematologiya = Oncohematology 2020;15(1):28–39. (In Russ.). DOI: 10.17650/1818-8346-2020-15-1-28-39.

58. Orlova R.V., Antimonik N.Yu., Pasekov D.S. et al. Successful treatment for patient with Erdheim–Chester syndrome. Meditsinskiy alfavit. Diagnostika i onkoterapiya = Medical Alphabet. Diagnostics & Cancer Therapy 2019;3(28):9–17. (In Russ.). DOI: 10.33667/20785631-2019-3-28(403)-9-17.